Trade

with

PDL BioPharma Inc
(NASDAQ: PDLI)
AdChoices
=
8.33
0.00
0.00%
After Hours :
8.33
0.00
0.00%

Open

8.18

Previous Close

8.33

Volume (Avg)

3.25M (3.18M)

Day's Range

8.17-8.60

52Wk Range

7.22-10.26

Market Cap.

1.34B

Dividend Rate (Yield )

0.60 (7.20%)

Beta

0.60

Shares Outstanding

160.64M

P/E Ratio (EPS)

5.04 (1.65)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 442.92M

    • Net Income

    • 264.53M

    • Market Cap.

    • 1.34B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 56.64

    • PEG (Price/Earnings Growth) Ratio

    • 0.17

    • Beta

    • 0.60

    • Forward P/E

    • 2.87

    • Price/Sales

    • 2.86

    • Price/Book Value

    • 4.51

    • Price/Cash flow

    • 5.60

      • EBITDA

      • 431.98M

      • Return on Capital %

      • 42.84

      • Return on Equity %

      • 191.10

      • Return on Assets %

      • 42.84

      • Book Value/Share

      • 1.85

      • Shares Outstanding

      • 160.64M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.15 (12/3/2014)

      • Dividend Declaration Date

      • 1/30/2014

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 2.90

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -19.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 25.00

          • 17.04

          • Net Income

            Q/Q (last year)

          • -1.80

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 8.52

          • 63.43

          • Net Income

            5-Year Annual Average

          • 2.10

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 98.87

            • 82.75

            • Pre-Tax Margin

            • 89.35

            • 39.38

            • Net Profit Margin

            • 56.64

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.70

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 78.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 51.50

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.92

              • 0.76

              • Current Ratio

              • 0.75

              • 2.92

              • Quick Ratio

              • 0.73

              • 2.35

              • Interest Coverage

              • 14.41

              • 38.02

              • Leverage Ratio

              • 3.09

              • 2.21

              • Book Value/Share

              • 1.85

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 5.04

                • 217.39

                • P/E Ratio 5-Year High

                • 6.21

                • 634.30

                • P/E Ratio 5-Year Low

                • 2.82

                • 124.82

                • Price/Sales Ratio

                • 2.86

                • 9.52

                • Price/Book Value

                • 4.51

                • 8.61

                • Price/Cash Flow Ratio

                • 5.60

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • 36.32

                    • Dividend Date

                    • 1/30/2014

                    • Ex-Dividend Date

                    • 12/3/2014

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • 191.10

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • 42.84

                        (61.80)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • 54.22

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • 28.23M

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.76

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      407.53M
                      Operating Margin
                      92.01
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      5.60
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      55.66%

                      Mutual Fund Ownership

                      49.91%

                      Float

                      87.88%

                      5% / Insider Ownership

                      2.49%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • First Trust NYSE Arca Biotech Fund

                      •  

                        6,357,447

                      • 2.03

                      • 4.41

                      • iShares Select Dividend

                      •  

                        5,950,767

                      • 0.37

                      • 4.13

                      • AEGON Intl Newton Real Ret

                      •  

                        5,779,778

                      • 0.00

                      • 3.61

                      • AEGON Intl Newton Global Higher Income

                      •  

                        4,734,720

                      • 0.00

                      • 2.95

                      • Vanguard Small Cap Index

                      •  

                        2,790,190

                      • -0.33

                      • 1.74

                      • Vanguard Total Stock Mkt Idx

                      •  

                        2,707,023

                      • 0.00

                      • 1.69

                      • iShares Russell 2000 (AU)

                      •  

                        2,382,820

                      • -1.46

                      • 1.65

                      • iShares Nasdaq Biotechnology

                      •  

                        2,078,229

                      • -0.47

                      • 1.44

                      • Schroder Glb Quant Act Val

                      •  

                        1,638,333

                      • 0.00

                      • 1.02

                      • Vanguard Small Cap Value Index Fund

                      •  

                        1,497,908

                      • 1.36

                      • 0.93

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Charger Corp.

                      •  

                        16,336,458

                      • +31.33%

                      • 10.17

                      • Renaissance Technologies Corp

                      •  

                        12,896,754

                      • +8.75%

                      • 8.05

                      • Newton Management Ltd

                      •  

                        12,343,629

                      • -2.24%

                      • 7.70

                      • BlackRock Fund Advisors

                      •  

                        11,384,180

                      • -1.11%

                      • 7.10

                      • Vanguard Group, Inc.

                      •  

                        10,169,706

                      • +2.13%

                      • 6.35

                      • Schroder Investment Management Ltd.

                      •  

                        8,092,140

                      • -0.63%

                      • 5.05

                      • Acadian Asset Management LLC

                      •  

                        6,593,444

                      • +1.64%

                      • 4.10

                      • Advisors Asset Management

                      •  

                        4,727,365

                      • +28.62%

                      • 2.95

                      • State Street Corp

                      •  

                        3,591,951

                      • -1.90%

                      • 2.24

                      • Wells Fargo Bank NA

                      •  

                        3,128,123

                      • +61.28%

                      • 1.95

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      High Yield

                      Style

                      Small Core

                      PDL BioPharma, Inc., was organized as a Delaware corporation in 1986 under the name Protein Design Labs, Inc. In 2006, the Company changed its name to PDL BioPharma, Inc. The Company is engaged in the discovery of a new generation of...more targeted treatments for cancer and immunologic diseases. The Company focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. It manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents, covers among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in human...moreized antibodies and methods of producing humanized antibodies. It’s U.S. Patent; covers methods and materials used in the manufacture of humanized antibodies. The Company entered into licensing agreements under Queen et al. patents with entities that are independently developing or have developed humanized antibodies. The Company entered into patents license agreement with Genentech, Biogen Idec and Chugai; and it entered into a royalty purchase and sale agreement with Depomed, Inc. As on year ended December 31, 2013, the Company received Queen et al. patent royalties on sales of the eight humanized antibody products, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States; including, Avastin®, Herceptin®, Xolair®, Lucentis®, Perjeta®, Kadcyla®, Tysabri® and Actemra®. The Company has also entered into licensing agreements under which it has licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials. The Company faces competition from other royalty buyers and enterprises. The Company’s licensees, borrowers and royalty-agreement counterparties are subject to stringent regulation with respect to product safety and efficacy by various international, federal, state and local authorities.lessless

                      Key People

                      Mr. John P. Mclaughlin

                      CEO/Director/President

                      Mr. Peter S. Garcia

                      CFO/Vice President

                      Christopher L. Stone

                      General Counsel/Secretary/Vice President

                      Mr. Danny Hart

                      Vice President, Divisional

                      Mr. David W. Gryska

                      Director

                      • PDL BioPharma Inc

                      • 932 Southwood Boulevard

                      • Incline Villiage, NV 89451

                      • USA.Map

                      • Phone: +1 775 832-8500

                      • Fax: +1 775 832-8501

                      • pdl.com

                      Incorporated

                      1986

                      Employees

                      10

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: